NCT06887322Enrolling by invitationPhase 1/2
The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions
The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Modified Psoriasis Area and Severity Index, Thickness, and Inflammation of Psoriasis Vulgaris Lesions
Source: ClinicalTrials.gov · Last updated 1 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy. Various inflammatory mediators that activate and are produced from the NF-κB signaling pathway play a role in the pathogenesis of psoriasis vulgaris. Topical corticosteroids are the first-line therapy for all severity levels of psoriasis vulgaris, possessing immunosuppressive, anti-inflammatory, and antimitotic effects. However, long-term use can lead to side effects such as atrophy, striae, telangiectasia, hypopigmentation, acneiform eruptions, perioral dermatitis, and hypertrichosis.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 13 Mar 2025
- Start date
- 13 Feb 2025
- Primary completion date
- 10 Apr 2025
- Lead sponsor
- Universitas Padjadjaran
- Diseases
- Psoriasis
- NCT number
- NCT06887322
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 40
- From 13 Feb 2025 to the primary completion date, 10 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently undergoing systemic therapy for psoriasis vulgaris.
- Patients who have not discontinued systemic therapy/phototherapy for psoriasis vulgaris ≤ 30 days.
- Patients with psoriasis vulgaris who have not discontinued topical therapy (other than moisturizers) ≤ 14 days.
Other
- Pregnant or breastfeeding women.
- Psoriasis vulgaris lesions located in trauma-prone areas, palms, soles, face, and skin folds.
Who the study is looking for
- Age 18 - 60 years
- Diagnosed with psoriasis vulgaris based on medical history, physical examination, and severity assessment using the PASI score
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hasan sadikin general hospital Coordinator of this site? Confirm its status | Bandung | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.